CATEGORY

Companion Diagnostics

Use of assays for gene specific diseases.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Companion Diagnostics.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Companion Diagnostics Suppliers


    Companion Diagnostics Supplier

    Find the right-fit companion diagnostics supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Companion Diagnostics market report transcript


    Global Market Outlook on Companion Diagnostics

    Companion diagnostic market was $5.8 billion in 2017 and will grow at a CAGR of 22.7 percent during 2018–2023. North America holds the largest market share, accounting approximately 35–40 percent of the global market.Increasing demand for personalized medicines and growing awareness among the population coupled with rising cases of adverse drug reactions related to drugs has been driving the need for companion diagnostics. Oncology accounts for the maximum market share (70 percent), in terms of indications, and is followed by other indications, like neurology, infectious disease, and cardiovascular.

    Over 30 percent of new drug approved in 2017 were personalized medicines. The therapies approved in 2017 targeted cancer (e.g., breast cancer, metastatic Merkel cell carcinoma, non-small cell lung cancer, and myeloid leukemia), orphan diseases (e.g., CLN2 batten disease and mucopolysaccharidosis type VII (Sly syndrome), and infectious disease, such as hepatitis C.

    • Next generation sequencing and liquid biopsy are the technology catalysts for companion diagnostics
    • All the major suppliers have competitive technology and compete with each other for partnership with biopharmaceutical clients
    • Partnership deals are common, and many biopharma have multiple partners for the development of companion diagnostics

    Precision Medicine Trends

    Precision medicine beyond oncology

    • Oncology currently dominate the precision medicine and companion biomarker research space for targeted therapeutics, However, there has been a shift in industry to other therapeutic areas, like diabetes, inflammatory diseases, neurosciences, and infectious diseases (HIV and hepatitis)
    • Recent study has suggested that 93 percent of the current phase 3 pipelines are diagnostic dependent (i.e., targeted therapeutics) and about two-thirds are focused on non-oncology areas

    Precision medicine harnessing big data capabilities

    • Precision medicine holds the promise of looking beyond the intrinsic omics factors and incorporating exogenous endpoints by capturing critical data, such as family history, food habits, alcohol intake, smoking, weight, salt intake, activity, etc., utilizing big health platforms
    • E.g., there are many innovative digital health coaching platforms available and many alternative therapies for the prevention and management of acute chronic health conditions, like wellness programs with proven behavioral therapies, such as Omada (digital behavioral therapies for diabetes patients) and Zipongo (personalized nutrition solutions)

    Precision medicine boosting healthcare consumerism

    • With digital healthcare solutions, people are becoming more receptive to healthcare information and want to actively participate in their healthcare decision-making process
    • Precision medicine provides a sense of accountability for patients and their caregivers through evolving consumer-centric care business models, such as direct-to-consumer (DTC) diagnostics, telehealth, and e-prescriptions, which promotes awareness and cost transparency for lab procedures, hospital visits, and medications.
    • This, in turn, will provides patients with greater clarity about the actual cost of care for their specific health condition, making them more conscious of their health, and therefore, reducing the overall cost burden